GO306
AXP000109.1 · Oncolytic virus
- Platform
- vaccinia virus
- Originator
- GeneSail Biotech
- Sponsor
- GeneSail Biotech
Names
| Name | Type | Source |
|---|---|---|
| GO306 | preferred name, code | curator, ctgov |
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Replication
- conditionally replicating
- Modifications
- not described in the registration
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07128914 | A Clinical Study of GO306 in Patients With Advanced Solid Tumors | Recruiting | Phase 1 | 2025-07-31 | 2026-12-31 | 32 | Solid Tumor Malignancies |
Recent changes
No changes recorded in its trials yet.
Notes
Recombinant oncolytic vaccinia virus injection; phase 1 in advanced refractory solid tumours (NCT07128914, recruiting since August 2025). Construct and route not described.
How to cite
GO306 (AXP000109.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000109.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.